Movement Disorders Flashcards
Movement disorders
group of diseases that primarily involve subcortical brain structures that are part of the extrapyramidal motor system, including the basal ganglia (caudate, putamen, and globus pallidus), thalamic and subthalamic nucleus, and substantia nigra, and their interconnections to each other and cortex
extrapyramidal motor system regulates movement and maintains muscle tone and posture.
Three primary neurotransmitters of the basal ganglia that contribute to symptomatology of movement disorders
Dopamine (inhibitory)
acetylcholine (excitatory)
gamma-aminobutyric acid (GABA; inhibitory)
Parkinson’s Disease
neurodegenerative disorder characterized by:
parkinsonism (rest tremors-most common and generally asymmetrical, slowness/bradykinesia, rigidity)
neuronal loss in the substantia nigra,
dopamine depletion in the striatum (and a clear and dramatic beneficial response to dopaminergic therapy)
frontal subcortical circuitry dysfunction.
Risk factors for Parkinson’s Disease
viral encephalitis,
drugs with dopamine antagonistic properties (neuroleptics),
toxic substances, exposure to herbicides, pesticides, and heavy metals drinking of contaminated well water
Medication for Parkinson’s Disease
levodopa, dopamine agonists, and
MAO-B inhibitors.
Nonpharmacological Interventions for Parkinson’s disease
Physical exercise (especially exercises designed to improve balance,
flexibility, and strength),
cued exercises with visual (mirror),
voice therapy,
speech/swallowing therapy,
Deep brain stimulation (DBS) -
Best candidates have severe motor symptoms in the off-medication condition; targets include subthalamic nucleus or globus pallidus as the most common sites, although
ventrointermedius (VIM) thalamic nucleus has clear effect on tremor; dementia is usually a
contraindication for DBS.
neuropsychological expectations for Parkinson’s disease
Impaired: complex attention, working memory, processing speed/EF, initial memory
Language: dysarthria and reduced speech output; comprehension, syntax, and grammar intact
Visuospatial: micrographia, difficulties with constructional praxis
Depression and anxiety common
Huntington’s Disease
fatal autosomal dominant neurodegenerative disorder
CAG repeats on chromosome 4 - can be diagnosed by genetic testing
Symptoms: chorea (jerky involuntary movements), dystonia, tic, incoordination, hypokinesia, saccades
Mean age at onset between 30–50
apathy
Disease duration is 15–20 years. Causes of death include pneumonia (related to dysphagia), heart disease, and suicide
Neuropathology of Huntington’s disease
loss of cells caudate nucleus and putamen.
As the disease progresses, further degeneration is observed in erebral cortex, thalamus, pallidum, brainstem, and cerebellum.
Medication for Huntington’s disease
Chorea may be treated with tetrabenazine (TBZ), a dopamine-depleting agent.
botulinum toxin injections for muscle spasms/spasticity in later stage of HD
SSRIs may be helpful for depression and anxiety but increase for suicide
Huntington’s disease neuropsychological outcomes
Impaired early:
visual attention,
processing speed,
visuospatial integration,
deficits in learning but recognition intact until middle/late stages,
working memory/EF severely impaired
Depression, anxiety, psychosis, OCD
Lewy body disease (LBD)
progressive neurodegenerative disorder that is characterized by parkinsonism and cognitive decline/dementia.
Mean age of onset 50s-80s
Responsible for 20% or more of all dementias, second to AD.
Lewy body disease (LBD) neuropathology
Lewy bodies - abnormal aggregates of protein that form within nerve cells and displace other cell components;
alpha-synuclein is the primary component)
Lewy neuritis (LN; alpha-synuclein cytoplasmic inclusion
bodies) in the cortex and brainstem
Medication for Lewy body disease (LBD)
- Treatment of motor symptoms with levodopa can aggravate hallucinations.
- Treatment with dopamine agonists can result in compulsive behaviors
Lewy body disease/dementia course
slow progression, but with frequent fluctuations whereby the patient may have episodes of marked confusion/attention/alertness interspersed with periods of complete lucidity.